Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beta Agonist Lung Injury Trial – Prevention Study
2007-004096-19Phase 3Completed
- Sponsor
- Heartlands Hospital
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of salmeterol in acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), sponsored by Heartlands Hospital. Primary endpoint: Clinically significant acute lung injury within 72 hours of oesophagectomy. Started Feb 2008; status: completed.
02
Drugs
salmeterol
03
Conditions
acute respiratory distress syndrome (ARDS)acute lung injury (ALI)
Beyond the preview
Go deeper on 2007-004096-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004096-19.